Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: iPSC derived engineered T cell immunotherapies - Fate Therapeutics/Ono Pharmaceuticals

Next Previous
Drug Profile

Research programme: iPSC derived engineered T cell immunotherapies - Fate Therapeutics/Ono Pharmaceuticals

Alternative Names: CAR targeted, TCR-null CD8αβ+ T cells; FT 8xx; FT-ONO1; FT-ONO2; FT817; FT896; FT8solid; TCRless + TRAC-CARsolid + USE; TCRless TRAC-Targeted CAR-BCMA; TCRless TRAC-Targeted CAR19 + USE

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Fate Therapeutics; Ono Pharmaceutical
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in Japan (Parenteral)
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 28 Jun 2022 Fate Therapeutics expanded development and commercialisation agreement with ONO Pharmaceutical for the development of CAR NK and CAR T-celll cancer immunotherapies in

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top